Prisinformation från TradingView

Bolagspresentation:

Nyhetsflöde Gasporox

Related articles:
4/23/2024 11:45:27 AM - Gasporox: Executing its long-term strategy - Redeye - Gasporox’s results closely align with RRe expectations, showing seven quarters of positive EBITDA driven by sales from VialArch, GPX1500, and after-sales services. The company is preparing to launch a new version of VialArch in June and is already securing pre-orders from the pharma and beverage sectors. The upcoming debt maturity might pressure the share, while forthcoming earnings and order announcements could boost it.
4/23/2024 6:54:36 AM - Gasporox Q1 2024: Just as expected - Redeye - Redeye states the report aligned with its estimates, and Gasporox has now produced positive EBITDA seven consecutive quarters in a row, thus trending towards profitability. Sales were driven by VialArch, GPX1500 Vial, and after-sales. Gasporox, with SEK10.4m in cash and SEK12.8m in working capital, is financially stable but faces risks with a convertible loan that could be settled in cash if shares fall below SEK8.5. However, significant stakeholders might opt to increase their shares, and a non-specific contingency plan exists for such settlements.
2/16/2024 6:35:36 AM - Gasporox: Orders up, but earnings linger for 2024 - Redeye - Redeye states that net sales were slightly higher than expected, but OPEX was also higher. EBITDA was still in line. After a solid 2023, we believe 2024 will be a transitional year with continued net sales growth but higher OPEX. We estimate Gasporox’s order book to be SEK12.6m (35% of 2024e net sales). Redeye lowers its base case, but bull and bear cases remain unchanged.
2/15/2024 9:02:38 AM - Gasporox Q4 2023: Solid results and cash flow - Redeye - Redeye comments on Gasporox's Q4 report, which was in line with estimates. The quarter’s highlights were substantial working capital releases, resulting in solid CFFO. Going into 2024, Redeye estimates Gasporox has an order book standing at SEK12.6m, about 36% of its 2024 estimate. Redeye expects to make minor adjustments to its estimates and fair value range following the report.
12/14/2023 1:21:44 PM - Gasporox: Received the largest order in its history - Redeye - Gasporox has secured a SEK9.1m order for its VialArch product from MaxCann, with deliveries scheduled throughout 2024 in three batches. This follows a SEK4m order from MaxCann on August 28, 2023, indicating a trend of increasing order frequency and value. Gasporox's total orders for 2023/2024, including pending deliveries from MaxCann and Weber, amount to SEK16.1m. If half of these orders are fulfilled in 2023, the 2024 order book stands at SEK12.6m, which is 36% of the net sales forecast for 2024, with MaxCann orders comprising approximately 32% of these sales.
11/8/2023 7:30:08 AM - Gasporox: Catching its breath after a strong H1 2023 - Redeye - Redeye provides an update on Gasporox after its Q3 2023 report. The report came in weaker-than-expected after H1 2023 results exceeding our expectations significantly. While we are pleased by AutoMap already receiving orders worth SEK3m, we have less optimistic Gasporox will manage to grow in H1 2024 due to the strong 2023 results. Thus, we reduce our fair value range while we remain optimistic about the long-term.
11/7/2023 7:49:58 AM - Gasporox Q3 2023: Below expectations but still positive EBITDA - Redeye - Redeye comments on Gasporox Q3 2023 report which came in below estimates. with net sales growing 4% y/y and missing our estimates by 23%. EBITDA was positive for the fifth straight quarter (not adjusting for capitalized R&D), showing a 7% ETBIDA margin. We expect volatility in Gasporox's results and we expect to make only minior changes due to the report.
10/23/2023 8:54:03 AM - Gasporox: Quick comment on AutoMap agreement - Redeye - Redeye provides a quick comment on Gasporox’s AutoMap agreement worth SEK3m with Weber Maschinenbau GmbH (Weber), a distinguished German manufacturer specializing in food processing machinery. While we are surprised by the exclusivity clause, overall, we view the agreement as favorable. However, we refrain from updating our estimates or fair value range.
8/10/2023 5:20:27 AM - Gasporox Q2 2023: Sharp performance across the board - Redeye - Redeye provides an update after Gasprox’s Q2’23 report. We conclude the quarter was well above our expectations and that H1’23 performance was solid. We have also kicked the tires in the US and became more impressed by the product portfolio, while we expect the roll-out to be slow. We make minor adjustments to our estimates and reiterate the fair value range.
8/9/2023 7:16:07 AM - Gasporox Q2'23: Close to tripel digit beat on the top line - Redeye - Redeye comments on Gasporox’s Q2’23 report, which was significantly stronger than expected on all items. Sensors were the main driver of sales, while instruments also contributed positively. We are still cautious about extrapolating the results and will likely keep our current estimates and fair value range. However, we expect the share to close to our base case.
4/28/2023 7:47:51 AM - Gasporox: Best quarter yet - Redeye - Redeye comments on Gasporox Q1'23 report which beat expectations across the board. Gasporox is executing on the long-term opportunity, expanding its geographic reach and product portfolio. We make a slight negative revision to our Q2'23 esimate on the back of the strong Q1'23 report. We reiterate our base case of SEK25.
4/27/2023 8:21:09 AM - Gasporox: Three consecutive EBITDA-positive quarters - Redeye - Gasporox beat our expectations by 34% on the top line with positive quarterly EBITDA. Strong sales and better gross margin resulted in a strong EBITDA beat. However, we are cautious about extrapolating the trend, and our initial view is that part of the strong quarter was due to consuming the existing order book. We will likely keep our fair value range.
3/1/2023 6:46:48 AM - Gasporox: Managed for long-term value creation - Redeye - Redeye comments on Gasporox Q4'22 report which came in lighter than expected. However, our view is that the Company is investing for sustained long-term growth and one quarter should not be viewed in isolation. Overall, we reduce our net sales 2023e-2025e by 17%-20% and reduce our Base case by 20%.
2/28/2023 7:57:47 AM - Gasporox: Weak quarter, strong order book - Redeye - Redeye states that the Q4 report was weaker than expected with net sales coming in 43% lower than expected and EBITDA 98% lower than expected. However, we believe most of the miss is due to high expectations on Q4 in particular while results are becoming more even over the year. We still believe the long-term story is intact and expect to raise H1'23 estimates while lower the Q4'23 estimates. We expect no to slight reduction in our Base Case.
11/14/2022 6:47:24 AM - Gasporox: Keeping its Phot-on the Gas - Redeye - Redeye states the Q3 report was strong across the board. The Company continues on its path of profitability with Gross profit-to-asset-ratio continuing to increase with higher revenue and gross margin. We adjust our estimates for Q4'22–Q4'23 and our fair value range.
11/10/2022 8:30:29 AM - Gasporox Q3’22: Significant Beat, Positive EBITDA - Redeye - Redeye states Gasporox report was strong with beats accross the board. As a result, we will review our short-term estimates and the fair value range.
9/15/2022 1:56:22 PM - Gasporox: Set to Issue Convertible Note - Redeye - Gasprox announced yesterday that it plans to issue a convertible note worth SEK 5.5m, directed toward two large shareholders and the CEO. As a result, we updated our fair value range.
9/2/2022 6:21:37 AM - Gasporox: Bright Future Ahead - Redeye - Redeye initiates coverage on Gasporox, a manufacturer of laser-based quality assurance and testing equipment. Gasporox is set to achieve high incremental ROIC as it scales its fixed costs and expands its product offering.
12/1/2020 11:18:50 AM - Gasporox erhåller miljonorder om tidigare avtalad minimivolym för 2021 - Gasporox har erhållit en order om 3,6 miljoner kronor som en del av ett avtal från 2016 där ordern avser en avtalad minimivolym till och med september 2021. Det framgår av ett pressmeddelande.
9/9/2020 8:00:47 AM - GPX Medical ska noteras på First North (uppdatering) - (Uppdatering av nyhet från 4 september, har förtydligat att Gasporox numera inte äger några aktier i GPX efter att ha delat ut innehavet till sina ägare)
9/4/2020 9:21:42 AM - GPX Medical ska noteras på First North - GPX Medical avser att börsnotera sina aktier på Nasdaq First North med förväntad första handelsdag den 2 oktober. Det framgår av ett pressmeddelande.
8/18/2020 8:40:01 AM - 19 aktier har hittills i dag noterat nytt 52-veckorshögsta på Stockholmsbörsen - Hittills i dag har det bjudits på 19 nya 52-veckorshögsta på Stockholmsbörsens listor.
8/17/2020 8:40:37 AM - 22 aktier har hittills i dag noterat nytt 52-veckorshögsta på Stockholmsbörsen - Hittills i dag har det bjudits på 22 nya 52-veckorshögsta på Stockholmsbörsens listor.
8/14/2020 8:39:35 AM - 14 aktier har hittills i dag noterat nytt 52-veckorshögsta på Stockholmsbörsen - Hittills i dag har det bjudits på 14 nya 52-veckorshögsta på Stockholmsbörsens listor.
3/4/2020 11:47:55 AM - GPX Medical planerar för en CE-märkning av Neola 2023, huvudspåret är notering – vd - GPX Medical planerar för en CE-märkning av Neola 2023, huvudspåret är notering – vd
5/15/2018 1:24:31 PM - Gasporox behöver inte ta in mer kapital under överskådlig framtid efter emissionen – finanschef - Gasporox behöver inte ta in mer kapital under överskådlig framtid efter emissionen – finanschef